![Mitchell Chan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mitchell Chan
Director/Miembro de la Junta en AVALO THERAPEUTICS, INC. .
Fortuna: - $ al 31/05/2024
Cargos activos de Mitchell Chan
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
AVALO THERAPEUTICS, INC. | Director/Miembro de la Junta | 01/12/2021 | - |
Independent Dir/Board Member | 01/12/2021 | - | |
Maryland Technology Council
![]() Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services The Maryland Technology Council functions as a technology trade association. The private company is based in Rockville, MD. | Director/Miembro de la Junta | 11/03/2020 | - |
Historial de carrera de Mitchell Chan
Antiguos cargos conocidos de Mitchell Chan.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
VIELA BIO, INC. | Comptroller/Controller/Auditor | 01/06/2019 | 15/03/2021 |
Director Financiero/CFO | 01/06/2019 | 15/03/2021 | |
ASTRAZENECA PLC | Contacto de Relaciones con Inversores | - | - |
Formación de Mitchell Chan.
Rotman School of Management | Masters Business Admin |
University of Toronto | Graduate Degree |
Estadísticas
Internacional
Estados Unidos | 4 |
Canadá | 3 |
Reino Unido | 2 |
Operativa
Director/Board Member | 2 |
Comptroller/Controller/Auditor | 1 |
Director of Finance/CFO | 1 |
Sectorial
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
ASTRAZENECA PLC | Health Technology |
AVALO THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Viela Bio, Inc.
![]() Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
Maryland Technology Council
![]() Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services The Maryland Technology Council functions as a technology trade association. The private company is based in Rockville, MD. | Commercial Services |
- Bolsa de valores
- Insiders
- Mitchell Chan
- Experiencia